52
Participants
Start Date
November 30, 2010
Primary Completion Date
June 30, 2013
Study Completion Date
June 30, 2013
Brincidofovir
"* Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
Placebo
"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
Memorial Sloan Kettering, New York
New York Medical College, Valhalla
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
The Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Duke University Medical Center, Durham
Children's Hospital of Alabama, Birmingham
Vanderbilt University Medical Center, Nashville
St. Judes Children's Research Hospital, Memphis
Cleveland Clinic, Cleveland
Cincinnati Childrens Hospital, Cincinnati
Indiana University, Indianapolis
Univeristy of Minnesota, Minneapolis
St. Louis Children's Hosptial, St Louis
LSU Health Sciences Center New Orleans Childrens Hospital, New Orleans
UT Southwestern, Dallas
Baylor College of Medicine, Texas Childrens Hospital, Houston
MD Anderson Cancer Center, Houston
Methodist Hospital, San Antonio
The Children's Hospital-Denver, Aurora
Primary Children's Medical of Utah, Salt Lake City
Pheonix Children's Hospital, Phoenix
Childrens hospital of LA, Los Angeles
City of Hope National Medical Center, Duarte
CHOC Children's Hospital, Orange
University of California, San Francisco, San Francisco
Lucile Packard Childrens hopsital at Stanford, Stanford
Seattle Cancer Care Alliance, Seattle
Harvard-Children's Hospital Boston, Boston
Hackensack University Medical Center, Hackensack
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY